PD-L1 overexpression is observed in immune cells of malignant neoplasm, such as melanoma [14], renal cell carcinoma [15] and nonsmall cell lung carcinoma [16], which lead to downregulation of host response against the tumour. This evidence concerns the gene CD274 and renal cell carcinoma.